Dr. Natasha Dhawan, MD

Dr. Dhawan practices at Bronson Methodist Hospital in Kalamazoo, Michigan, part of Bronson Healthcare Group.

Dr. Dhawan's NPI, 1932559531, was assigned on June 15, 2016. Dr. Dhawan holds Michigan license 4301509528.

Dr. Dhawan's primary practice is Bronson Methodist Hospital, at 601 John Street, Kalamazoo, MI 49007 in Kalamazoo County. The practice phone is (269) 341-6000.

Dr. Dhawan's primary practice is Bronson Methodist Hospital in Kalamazoo, Michigan, part of Bronson Healthcare Group. Dr. Dhawan is also affiliated with Beacon Kalamazoo. The medical group on file is Bronson Medical Group. Dmand AI also links Dr. Dhawan to 3 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dhawan practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Dhawan's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Dhawan is licensed in Michigan.

CMS data shows 1,149 Medicare services from Dr. Dhawan across 7 procedure codes in 2024, for 128 Medicare patients. Medicare paid $72,831 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 128 Medicare patients who saw Dr. Dhawan in 2024. The largest group is 65 to 74, with 70 patients. 75% of them have high blood pressure, and 67% have high cholesterol. 13% are also on Medicaid. Their average risk score is 1.84, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dhawan's median patient age at 72, with 42% women.

In 2024, Dr. Dhawan wrote 933 Medicare Part D claims for 150 patients. 90% of them were for generic drugs. CMS names the drug for 732 of them, across 19 drugs with 11 or more claims each, at $89,378 in total drug cost. In 2023, CMS named 91 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Dhawan for performance year 2024, reported as part of a group. Dr. Dhawan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dhawan as offering telehealth.

Dmand AI links 15 papers to Dr. Dhawan, published from 2014 to 2023. 2021 was the busiest year, with 4. The most frequent topics are COVID-19, Hematology and Medical Oncology. Dr. Dhawan has published most often in Cancer Invest. Dr. Dhawan's most frequent co-authors are Christian T. Sinclair, MD, Eric Ernest Prommer, MD and Ishwaria Mohan Subbiah, MD, MS.

CMS Open Payments shows 135 general payments to Dr. Dhawan from 40 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 87% of the total. Novartis Pharmaceuticals Corporation paid the most, $434.